Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens
Patient-derived xenografts (PDX) are clinically relevant human cancer models that can be used to guide individualized medicine. We aimed to generate PDX models from clinically obtained biopsy specimens (surgical or image-guided) hypothesizing that low volume biopsy specimens could provide sufficient viable tissue to successfully engraft PDX models from patients with unresectable or metastatic disease.
Materials and Methods
We maintain a prospective high volume gastrointestinal malignancy PDX program. With informed consent and institutional approval, biopsy specimens (surgical or image-guided) were obtained from patients with unresectable or metastatic tumors: pancreatic adenocarcinoma (PDAC), cholangiocarcinoma, gastric and gallbladder carcinoma. Biopsies were implanted into immunodeficient mice. Tumor growth was monitored, viable tumor was passed into subsequent generations, and histopathology was confirmed.
In this study, biopsy specimens from 29 patients were used for PDX engraftment. Successful PDX engraftment was variable with highest engraftment rates in gastric and gallbladder carcinoma specimens (100%) compared to engraftment rates of 33% and 29% in PDAC and cholangiocarcinoma respectively. PDX models created from metastasis biopsies compared to unresectable primary tumor tissue demonstrated higher engraftment rates (69% versus 15.4%, p = 0.001). PDX models demonstrated higher engraftment rates when biopsies were obtained during surgical operations (n = 15) compared to image-guided (n = 14) (73% versus 14%, p = 0.003). Patient age, pretreatment status, or ischemic time was not different between biopsy methods.
PDX models can be successfully created from clinical biopsy specimens in patients with metastatic or unresectable GI cancers. The use of clinical biopsy specimens for PDX engraftment can expand the repertoire of stage-specific PDX models for downstream basic/translational research.
KeywordsPDX Biopsy, patient derived xenograft Unresectable FNA
Study design was developed by MCH, LY, JRB, and MJT. Data generation was performed by MCH, TI, LY, MJT, MLK, RLS, SPC, and DMN. Data analysis and interpretation were performed by MCH, LY, JLL, JRB, and MJT. Manuscript writing was performed by MCH, TI, LY, MJT, JRB, JLL, MLK, RLS, SPC, and DMN.
The authors acknowledge funding from Roger Thrun and the Mayo Clinic Clinician Investigator program.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Tentler JJ, Tan AC, Weekes CD, et al. Development 2014;9(6):338–350. doi: https://doi.org/10.1038/nrclinonc.2012.61.Patient-derived. Google Scholar
- 4.Daniel VC, Marchionni L, Hierman JS, et al. NIH Public Access. 2010;69(8). doi: https://doi.org/10.1158/0008-5472.CAN-08-4210.A.
- 11.Allaway RJ, Fischer DA, Abreu FB de, et al. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget 2016;7(13):17087–17102. doi: https://doi.org/10.18632/oncotarget.7718.CrossRefGoogle Scholar
- 12.Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res 2014;74(11):2913–2921. doi: https://doi.org/10.1158/0008-5472.CAN-14-0155.CrossRefGoogle Scholar
- 13.Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001;7(7):2076–2084. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11448926. Accessed 1 Oct 2017.Google Scholar
- 14.Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing internationalJ Hepatol trends in mortality rates for liver, biliary and pancreatic tumours. 2002;37(6):806–813. doi: https://doi.org/10.1016/S0168-8278(02)00297-0.
- 18.Amin MB, Edge SB, Greene FL, et al, eds. AJCC cancer staging manual. 8th edn. New York: Springer; 2017.Google Scholar
- 20.Hidalgo M, Amant F, Biankin a. V., et al. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discov 2014:998–1013. doi: https://doi.org/10.1158/2159-8290.CD-14-0001.
- 22.Chen J, Jiang K, Wu J, et al. Application of intraoperative transluminal core-biopsy for diagnosis of pancreatic head mass: A single center 15-year experience. Pancreatology 2017:1–5. doi: https://doi.org/10.1016/j.pan.2017.09.001.
- 25.Allaway RJ, Fischer DA, de Abreu FB, et al. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget 2016;7(13):17087–17102. doi: https://doi.org/10.18632/oncotarget.7718.CrossRefGoogle Scholar
- 32.Brandi G, Venturi M, Pantaleo MA, et al. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center. Dig Liver Dis. 2016;48(3):231–241. doi: https://doi.org/10.1016/j.dld.2015.11.017.CrossRefGoogle Scholar